Niraparib

National Prostate Cancer Awareness Month is observed every September.

Niraparib did not significantly extend OS among women with recurrent ovarian cancer, according to long-term follow-up results of the ENGOT-OV16/NOVA trial presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

SAN FRANCISCO — The addition of niraparib to abiraterone acetate and prednisone improved multiple outcomes for certain men with metastatic castration-resistant prostate cancer, according to randomized phase 3 study results.

In this video, Kim A. Reiss, MD, discussed the results of a randomized phase 1b/2 study of niraparib plus nivolumab or ipilimumab in patients with advanced pancreatic cancer, which were presented in a poster session at ASCO2022.

SAN FRANCISCO — The addition of niraparib to best supportive care failed to extend PFS among patients with advanced urothelial carcinoma who did not experience progression after first-line platinum-based chemotherapy, study results showed.

SAN FRANCISCO  — The addition of niraparib to abiraterone acetate and prednisone improved outcomes for certain men with prostate cancer, according to randomized phase 3 study results presented at ASCO Genitourinary Cancers Symposium.

Patients with gynecologic cancers that responded to first-line platinum-based chemotherapy receiving niraparib did not show lower health-related quality of life compared with placebo, according to data presented at ESMO Virtual Congress 2020.

The FDA approved niraparib for first-line maintenance treatment of certain women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancers.

The FDA accepted a supplemental new drug application for niraparib as first-line maintenance treatment of women with platinum-responsive advanced ovarian cancer.

In this supplement to HemOnc Today, we have compiled the most-read articles written about ovarian cancer this year. From risk reducing measures (below) to improving progression-free survival (pages 12 and 14), our experts researched and weighed in on the spectrum of this deadly carcinoma. “These are exciting times in ovarian cancer research and, more importantly, for patients. Recent discoveries have realized the possibility that this is the beginning of the end of ovarian cancer,” Michael J. Birrer, MD, PhD, writes in his editorial (page 10). “Our new understanding of the origins of this disease may give rise to a reasonably effective early detection assay, which remains the holy grail of ovarian cancer research.” To follow along this journey, be sure to follow @HemOncToday on Twitter and visit Healio.com regularly.